[Allomap genetic test for cardiac transplant rejection]

Carballido Fernández M, Llanos Méndez A
Record ID 32013000370
Authors' objectives: The Allomap™ test is a panel of genes faced with a blood sample which tries to distinguish between acute rejection moderate / severe and the absence of rejection, and thus be an alternative to endomyocardial biopsy. The aim of the systematic review was to assess the efficacy, effectiveness, and safety of the Allomap™ test for the diagnosis of acute cellular rejection in heart transplant recipients.
Authors' recommendations: A systematic review was performed and 2 evidence reports, 4 diagnostic test studies, 1 clinical trial and 1 description of costs study were selected. Methodological quality of the studies was adequate or high for the most of them. Diagnostic test studies reported the accuracy of the Allomap™ test showing low capacity in detecting the moderato/sever acute cellular rejection. Global accuracy outcomes were: sensitivity between 71% and 100%, specificity values between 42% and 79%, which makes it more suitable to rule out the disease. The positive likelihood ratios ranged between 1.3 and 3.6, while the negative likelihood ratios ranged from 0 to 0.58. The clinical trial evaluated the clinical utility (effectiveness) of the Allomap™ test. During a median follow-up period of 19 months, patients who were monitored with the Allomap™ test and those who underwent biopsies had similar risk of rejection (HR 1.04; 95% CI, 0.67-1.68) or death (HR 1.10; 95%CI: 0.50–2.40). Safety of the Allomap™ test has been demonstrated because of it is required for its implementation only a peripheral blood sample, as opposed to endomyocardial biopsy, which is an invasive test. Although the cost of the tests was similar, a description of cost study indicated an annual savings of $ 12 million in the U.S.A. to be needed a greater number of biopsies Allomap™ test.
Project Status: Completed
Year Published: 2012
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Gene Expression
  • Heart
  • Heart Transplantation
  • Predictive Value of Tests
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.